SOPHiA GENETICS SA
No enriched coverage for $SOPH in the last 7 days.
SOPHiA GENETICS SA (SOPH) reported Q2 2026 revenue of $23.3 million, up 27%, and an adjusted EBITDA loss of $8.8 million. Platform analysis volume rose 22% to 115,000 patient analyses. Management raised full-year revenue guidance to $94 million to $96 million and reaffirmed adjusted EBITDA loss of $29 million to $32 million, citing U.S. in-house testing demand and biopharma growth.
Biotech stocks hit 52-week highs Aug 4, 2026 after Q2 results or regulatory updates. UFP Technologies (UFPT) rose over 25% to $338.70, reporting Q2 net income $20.9M and sales $174M. InfuSystem (INFU) gained 33% to $12.49 on $36.9M Q2 revenue and 2026 guidance. Replimune (REPL) jumped to $13.86 after a favorable BLA opinion. SOPHiA (SOPH) rose to $6.98 with $23.3M Q2 revenue and 2026 outlook. Parabilis (PBLS) reached $36.69.
SOPHiA GENETICS (Nasdaq: SOPH) reported Q2 2026 revenue of $23.3 million, up 27% year over year, with gross margin of 64.6% reported and 72.1% adjusted. Net loss was $22.4 million and adjusted EBITDA loss was $8.8 million, improving 27%. The company raised 2026 revenue guidance to $94-$96 million and signed AstraZeneca companion diagnostic programs.
Recent SOPH coverage spans financial news, earnings and market movers.
In the last 30 days, SOPH insiders filed 19 SEC Form 4 transactions — no purchases and 19 sales ($1.1M). The most active reporter was Xu Zhenyu, Chief Scientific Officer, with 8 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Raised top-line outlook with improving operating leverage, but margin pressure persists and EBITDA loss remains expected through 2026.
Strong growth metrics and raised/affirmed guidance likely underpin the breakout and can sustain re-rating if execution continues.
Guidance raise plus improving adjusted EBITDA loss suggests improving operating leverage, supporting a bullish re-rating versus prior expectations.
The deal expands SOPHiA’s CDx pipeline and commercialization path via AstraZeneca, potentially improving near-to-mid-term revenue visibility tied to diagnostic development and deployment.
The move is supported by disclosed financial performance and explicit 2026 revenue guidance, improving visibility for growth.
alphai scores every news story that mentions SOPH with an AI model for sentiment and relevance, and aggregates insider trades from SOPHiA GENETICS SA's SEC EDGAR Form 4 filings. Figures refresh continuously.
SOPHiA GENETICS SA (SOPH) reported Q2 2026 revenue of $23.3 million, up 27%, and an adjusted EBITDA loss of $8.8 million. Platform analysis volume rose 22% to 115,000 patient analyses. Management raised full-year revenue guidance to $94 million to $96 million and reaffirmed adjusted EBITDA loss of $29 million to $32 million, citing U.S. in-house testing demand and biopharma growth.
6 min readBiotech stocks hit 52-week highs Aug 4, 2026 after Q2 results or regulatory updates. UFP Technologies (UFPT) rose over 25% to $338.70, reporting Q2 net income $20.9M and sales $174M. InfuSystem (INFU) gained 33% to $12.49 on $36.9M Q2 revenue and 2026 guidance. Replimune (REPL) jumped to $13.86 after a favorable BLA opinion. SOPHiA (SOPH) rose to $6.98 with $23.3M Q2 revenue and 2026 outlook. Parabilis (PBLS) reached $36.69.
6 min readSOPHiA GENETICS (Nasdaq: SOPH) reported Q2 2026 revenue of $23.3 million, up 27% year over year, with gross margin of 64.6% reported and 72.1% adjusted. Net loss was $22.4 million and adjusted EBITDA loss was $8.8 million, improving 27%. The company raised 2026 revenue guidance to $94-$96 million and signed AstraZeneca companion diagnostic programs.
6 min readSOPHiA GENETICS (NASDAQ: SOPH) said it entered a multi-year collaboration with AstraZeneca to develop, validate, and deploy two companion diagnostics for precision oncology therapies. SOPHiA will advance its Solid Tumor decentralized CDx and develop a Hematological Oncology application for blood cancer. The programs aim to support commercialization of AstraZeneca therapies.
4 min readBiotech stocks hit 52-week highs on July 20, 2026, attributed to upcoming clinical catalysts. Xencor (XNCR) reached $20.26, up 7%, with Phase 2b XENITH-UC interim results expected by year-end 2026. Hemab (COAG) hit $52.15 after positive Phase 2 Sutacimig data. Monopar (MNPR) hit $115 on Phase 3 ALXN1840 Wilson disease results. SOPHiA (SOPH) rose above $6.50; Q1 revenue was $21.7M and 2026 guidance is $92M to $94M.
4 min readCamblong Jurgi (Executive Chairman) sold 83,679 shares of SOPHiA GENETICS SA (SOPH) at an average of $6.06 ($5.87–$6.30, $0.51M total) across 5 trades over 2026-06-29 to 2026-06-30 under a Rule 10b5-1 trading plan.
2 min readReuters (May 27) reported Biohub, founded by Meta CEO Mark Zuckerberg and Priscilla Chan, developed an open-source global protein-biology model using fourth-generation evolutionary scale modeling (ESM) to speed drug discovery. Biohub said it will run via Biohub.ai and partners like AWS Bio Discovery, with computing credits, and expects broader lab use. The article also lists hedge-fund “AI drug discovery” holdings, including SOPHiA Genetics’ proposed MSK precision-oncology JV and Generate Biomed
6 min readSOPHiA GENETICS (Nasdaq: SOPH) said its 2026 Annual General Meeting approved all proposals. Shareholders elected co-founder Dr. Jurgi Camblong as Executive Chairman with 99.79% of votes and elected Ross Muken to the board with 99.88%; Muken becomes CEO effective July 1, 2026. Re-elected directors and compensation, auditor, and governance items were also approved.
3 min readSOPHiA GENETICS (Nasdaq: SOPH) said it closed an underwritten public offering after oversubscribed demand. The company sold 12,104,900 ordinary shares at $4.75 each, and underwriters fully exercised their option to buy an additional 1,578,900 shares. Gross proceeds were $57.5 million. TD Cowen led; Guggenheim, BTIG and Craig-Hallum also managed.
3 min readSOPHiA GENETICS (Nasdaq: SOPH) priced a previously announced underwritten public offering of 10,526,000 ordinary shares at $4.75 each, raising about $50 million in gross proceeds, according to the company. It also granted underwriters a 30-day option to buy up to 1,578,900 additional shares. The offering is expected to close June 18, 2026.
2 min read
